Point-of-care Management of Coagulopathy in Lung Transplantation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Point-of-care Management of Coagulopathy in Lung Transplantation (NCT03598907), a registered phase not stated study. The primary outcome is Perioperative Blood Loss.

2. Clinical Question

3. Trial Design

The study is titled as a randomized controlled study, and its brief summary describes a prospective randomized trial with two groups. However, allocation details are not reported in the registry record. The record’s design classification also cautions that allocation is not stated and that the arms are not a like-for-like control comparison. Those qualifications matter: the title and summary describe the intended design, but the available record does not establish how participants were assigned or whether the groups were comparable at baseline.

The groups are described as standard management of coagulopathy and point-of-care management of coagulopathy during lung transplantation. The standard-care description refers to clinical experience and names crystalloids, colloids, fresh frozen plasma and erythrocytes. The point-of-care description names ROTEM, PFA 200 and Multiplate testing and lists treatments guided by those results. These are different management strategies, not simply different labels for an otherwise identical procedure. Full treatment protocols and details about adherence are not reported in the registry record.

The record lists enrollment as 100. Its brief summary describes a trial of 120 patients, so the record contains differing enrollment figures; it does not explain their relationship. The primary endpoint population is described as randomized patients who underwent lung transplantation. The number meeting that definition is not reported in the registry record.

The study status is terminated. The record lists a start date of 2018-01-01 and a primary completion date of 2020-06-30. It does not report why the study was terminated or whether the listed completion date reflects completion of the planned enrollment or follow-up. There are five outcome measures listed and zero analyses reported. Numerical results for the primary endpoint are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Total number of patients anticipated in the study was 120, meaning 60 patients in every group.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All randomized patients who underwent lung transplantation

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Perioperative Blood Loss, measured over From the beginning of surgery to 24 hours postoperatively.

The primary endpoint is total estimated perioperative blood loss, measured in mL from the beginning of surgery to 24 hours postoperatively. Its description includes blood loss during the operation and the immediate postoperative period. The endpoint is specified as a continuous measure summarized by a mean and standard deviation, and its defined population is randomized patients who underwent lung transplantation.

In general, blood loss can serve as a measure of perioperative bleeding and may be relevant when comparing approaches intended to diagnose or manage coagulopathy. A mean describes the central level of the measured outcome across a group; a standard deviation describes how much individual observations vary around that mean. Neither statistic, alone, gives the full distribution of outcomes or establishes whether a group difference is precise.

The registry record does not report group means, standard deviations, the number of patients with endpoint data, or a between-group estimate with an uncertainty interval. It therefore does not allow readers to assess the observed blood-loss levels, the size or direction of a difference, or its precision. The endpoint definition also does not specify how estimated blood loss was measured or whether the same measurement procedure was used in both groups; those details are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

For a continuous endpoint such as perioperative blood loss, a common summary is the mean for each group, accompanied by a measure of spread such as the standard deviation. The mean indicates the average observed amount in the analyzed group. The standard deviation indicates how dispersed individual measurements are around that average. In general, these summaries help describe the data but do not by themselves show the uncertainty in the difference between groups. The registry record specifies a mean and standard deviation as the outcome measure’s summary, but it does not report the values.

What would a group comparison estimate?

In general, a between-group analysis would estimate a contrast in mean blood loss for the groups being compared. The estimate’s interpretation depends on the analysis population, assignment process, outcome measurement and model. A confidence interval would express the uncertainty around that estimate under the analysis assumptions. A narrow interval indicates greater precision than a wide interval, but precision is not the same as clinical importance. The registry record reports no estimated contrast or confidence interval for this endpoint, so neither precision nor the direction of the comparison can be evaluated.

Why does the allocation information matter?

Random assignment, when implemented and reported, can help balance characteristics that might otherwise differ between groups. It does not guarantee that every characteristic is balanced, especially in a modest study, and it does not remove the importance of reporting how assignment was carried out. Here, the study title and brief summary describe randomization, but the allocation method is not reported in the registry record. The record also cautions that the arms are not a like-for-like control comparison. Readers therefore cannot verify assignment procedures or judge whether differences between groups beyond the management strategy could influence the endpoint.

What assumptions underlie planning illustrations?

The record describes sample-size planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between the two arms and a normal approximation. The stated effect to detect is a fraction of the observed effect. In general, such calculations explore how many participants per arm would be needed under specified assumptions; they are not results from an actual trial analysis. They are not observed power, and they do not show that a study had a particular probability of detecting an effect after the data were collected. Because the registry record does not report the primary endpoint estimate or the numerical planning results, the assumptions and illustrations cannot be independently assessed from the listed endpoint results.

How should variation in blood loss be considered?

In general, continuous clinical outcomes can be skewed or contain values that differ markedly from the rest of the data. If the distribution is strongly asymmetric, the mean and standard deviation may not fully convey the typical experience or the range of observations. A model that assumes normally distributed errors may also require scrutiny if the data depart from that assumption. The record does not report the blood-loss distribution, diagnostic checks, transformations, robust methods or a nonparametric analysis. It is therefore not possible to determine which methods were used to address distributional features.

The endpoint description says that total estimated blood loss was measured across the intraoperative and immediate postoperative periods. In general, measurement definitions and consistency are important: differences in recording procedures could affect group summaries independently of the clinical process being studied. The registry record does not describe the measurement protocol, assessor masking or procedures for resolving incomplete measurements. It also does not report missing endpoint counts or how any missing values were handled.

Finally, the number of analyses reported is zero. This does not establish which analyses were conducted outside the registry, but it means their methods and results are not reported in the registry record. The record does not state whether the primary comparison was adjusted, whether an interim analysis was planned, or how multiple outcomes and tests were handled. Those omissions limit reproducibility and make it impossible to determine whether a reported result—if available elsewhere—would correspond to a prespecified analysis.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Non POC Group", "POC Group")
n   <- c(36, 31)
m   <- c(1043, 682)
sp  <- c(547, 399)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Non POC Group  36  1043.000  547.000  857.922  1228.078
CARM  POC Group  31  682.000  399.000  535.646  828.354

11. Multiplicity, Missing Data and Analysis Populations

The registry lists five outcome measures, but no analysis results are reported. It does not identify which outcomes were designated secondary, describe a hierarchy of hypotheses, or state whether any adjustment for multiple testing was planned. In general, when researchers test multiple outcomes or comparisons, the chance of at least one apparently unusual result can rise if each test is interpreted separately. Statistical procedures can address this issue, but the appropriate approach depends on the questions and analysis plan. No multiplicity strategy is reported in the registry record.

The primary endpoint population is described as randomized patients who underwent lung transplantation. The record does not report how many participants met that definition, how many had an available blood-loss measurement, or whether exclusions occurred after assignment. It also does not state whether the analysis followed an intention-to-treat principle or used another analysis population. Those details matter because an analysis limited to participants with observed outcomes may differ from one that retains everyone as assigned.

Missing-data methods are not reported in the registry record. The record does not say whether missing observations were expected, how their reasons were classified, or whether any imputation or sensitivity analysis was planned. In general, missing data can affect both estimates and their uncertainty, particularly when missingness is related to participants’ outcomes or clinical course. Without counts and methods, readers cannot assess the extent or potential impact of missing endpoint information.

Interim analyses, stopping rules and a statistical analysis plan are also not reported in the registry record. The terminated status does not explain whether any interim analysis occurred or whether it influenced the study’s course. These are unreported details, not evidence that a particular method was or was not used.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s safety figures list, for standard management, 50 participants at risk for serious events and 0 affected, 50 at risk for other events and 0 affected, and 0 deaths. For point-of-care management, the corresponding listed figures are 50 at risk for serious events and 0 affected, 50 at risk for other events and 0 affected, and 0 deaths. The registry lists no top serious-event terms.

These figures should be read as reported counts, not as proof that no adverse events of any kind occurred or that either management approach is without risk. The record does not describe the event definitions, ascertainment procedures, duration of safety observation or whether all participants were observed for the same period. The figures also do not provide enough information to estimate comparative safety precisely.

Zero affected participants in a registry count is not the same as evidence that the underlying risk is zero. In general, interpretation depends on the completeness of collection, the observation period and the number of participants with evaluable safety information. Those details are not reported in the registry record. The counts therefore describe the posted safety entries, with important context about event collection unavailable.

13. What the Result Does, and Does Not, Mean

The registry record establishes that perioperative blood loss was the stated primary endpoint and that the study compared standard management with a point-of-care approach during lung transplantation. It does not report the endpoint results. Therefore, it cannot show whether mean blood loss differed between the groups, how large any difference was, or how precise an estimate might be. The absence of a reported result is not evidence that the approaches produced the same outcome.

The record’s title and brief summary describe a randomized study, but allocation details are not reported, and the design note cautions that the arms are not a like-for-like control comparison. Without the assignment process, group characteristics, endpoint results and analysis methods, a causal interpretation cannot be established from the registry record. The description of an intervention or its rationale is not itself evidence that it changed blood loss or another outcome.

The study is marked terminated. The reason for termination is not reported in the registry record, so the status cannot be interpreted as a result, a safety signal or proof that the study was completed as intended. The record lists enrollment as 100, while its brief summary describes 120 patients; it does not explain the difference. The number included in the primary endpoint analysis is also not reported.

The safety entries show zero affected participants in the listed categories and zero deaths in each group. These counts do not demonstrate absence of risk, particularly because the registry does not report detailed event definitions or observation procedures. The record therefore supports a limited description of the planned comparison and posted safety counts, but not a conclusion about comparative effectiveness or safety.

In general, interpreting a clinical trial requires more than identifying its objective. Readers need the observed estimates, uncertainty, analysis population, missing-data information and enough design detail to judge the comparison. Those elements are not reported for the primary endpoint. Any sample-size calculation based on an observed effect is a planning illustration, not observed power and not a substitute for the missing outcome estimate.

14. Why This Trial Matters Statistically

This record illustrates why trial registration details and posted results answer different questions. The title and summary describe an intended comparison of two approaches to managing coagulopathy during lung transplantation. The primary endpoint is clearly identified as mean perioperative blood loss in mL over a specified period. But without the group summaries and an estimated contrast, the central statistical question remains unanswered in the registry record.

Design information is also consequential. The study is described as randomized in its title and summary, while allocation is not stated and the design note cautions that the arms are not a like-for-like control comparison. This makes clear why readers should distinguish an intended design from details that permit assessment of how the comparison was conducted. The record’s differing enrollment figures and absence of an endpoint analysis population further limit interpretation.

From a statistical perspective, a useful report would connect the outcome definition to the analyzed data: group summaries, a between-group estimate, an interval expressing uncertainty, and an explanation of who was included. The registry record does not report these for the primary endpoint. General explanations of means, variation, confidence intervals and planning calculations can clarify what those quantities would mean, but they cannot replace the trial’s outcome evidence.

The safety entries likewise show why counts need context. Zero affected participants are the reported figures, but event definitions, observation procedures and completeness are not described. A careful statistical reading distinguishes a recorded zero from a demonstrated absence of risk. The terminated status also needs explanation before it can be interpreted; no reason is reported.

The main statistical lesson is that a stated hypothesis, a named endpoint and planning assumptions do not establish a result. Transparent outcome reporting and analysis details are needed to judge magnitude, precision, robustness and relevance. Those details are not reported in the registry record for this trial’s primary endpoint.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation for interpretation is that no numerical result for the primary endpoint is reported in the registry record. Group means, standard deviations, an effect estimate, uncertainty intervals and a statistical test result are absent. The registry lists zero analyses, so no analysis result can be evaluated against the stated endpoint.

Several design and population details are also unavailable. The record describes the trial as randomized in its title and summary, but allocation details are not reported, and its design note cautions that the arms are not a like-for-like control comparison. The record lists enrollment as 100, whereas the brief summary refers to 120 patients. It does not explain the difference or report the number included in the primary endpoint population.

The endpoint is defined as total estimated blood loss during surgery and the immediate postoperative period, but the method for estimating and recording blood loss is not described. The record does not report whether measurement was standardized, whether assessors were masked, or how incomplete measurements were handled. Missing-data methods, the analysis population, model specification and any adjustment for baseline characteristics are not reported in the registry record.

The trial is marked terminated, but the reason is not reported. The record also does not state whether interim analyses or stopping rules were used. It lists five outcome measures without describing a multiplicity strategy or analysis hierarchy. These omissions prevent assessment of whether the posted analyses, if any, followed a prespecified plan.

Safety interpretation is limited by the absence of detailed event definitions, ascertainment procedures and observation-period information. Finally, the registry’s stated planning assumptions do not compensate for missing trial results; planning illustrations are not observed power. Together, these gaps mean the record supports a description of the intended study and listed counts, but not a quantitative assessment of the primary comparison.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Point-of-care Management of Coagulopathy in Lung Transplantation — NCT03598907.
• Registry record last updated 2025-06-10; status last verified 2025-06.
• Results first posted 2025-05-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a study of standard and point-of-care management of coagulopathy during lung transplantation. It names mean perioperative blood loss, measured from the beginning of surgery to 24 hours postoperatively, as the primary endpoint. The study is marked terminated, and the record lists enrollment as 100; its brief summary refers to 120 patients.

The title and summary describe a randomized study, but allocation details are not reported in the registry record. The record cautions that the arms are not a like-for-like control comparison. Five outcome measures are listed, with zero analyses reported. No numerical results for the primary endpoint are reported, so the group comparison cannot be quantified. Listed safety counts show zero affected participants and zero deaths in each group, with further event-collection details not reported.